Acadia Is Starting Phase 3 Trial of Nuplazid for Dementia-related Psychosis

Acadia Is Starting Phase 3 Trial of Nuplazid for Dementia-related Psychosis
Acadia Pharmaceuticals is starting its Phase 3 HARMONY trial to evaluate Nuplazid (pimavanserin) as a treatment for hallucinations and delusions associated with dementia-related psychosis. Currently, there is no approved therapy for this condition. Acadia's announcement comes in the wake of the U.S. Food and Drug Administration designating Nuplazid a Breakthrough Therapy, which helps expedite its regulatory review and development. The FDA approved Nuplazid in April 2016 to treat 
Subscribe or to access all post and page content.